This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (5)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Genetics  • Genetic Counseling/ Testing/ Therapy  • Alert me on articles by topic  Social Bookmarking   What's this?

Scott A. Waldman, MD, PhD; Andre Terzic, MD, PhD

JAMA. 2007;297:1923-1925.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the United States, cancer is the second leading cause of death, exceeded only by cardiovascular disease, and an estimated 500 000 patients with cancer will die this year.^1-2 After cardiovascular and infectious diseases, cancer is the third leading cause of mortality worldwide.³ However, the field of clinical oncology is poised for unprecedented innovation, reflecting the confluence of breakthroughs in decoding disease pathobiology in the context of high-throughput enabling technologies.⁴ Harnessing the full potential of transformative advances is predicated on defining biomarkers that promote targeted cancer prevention, diagnosis, and treatment of individual patients and populations.^4-5 A new generation of molecular technologies, including genomic, proteomic, and metabolomic mapping, hold the promise of translating into practice the use of biomarker panels for increased diagnostic and therapeutic sensitivity and specificity.^{2, 4} Yet essential elements have resisted definition in developing mechanism-based molecular markers for individualized management of . . . [Full Text of this Article]

Author Affiliations: Departments of Pharmacology and Experimental Therapeutics and Medicine, Thomas Jefferson University, Philadelphia, Pa (Dr Waldman); and Departments of Medicine, Molecular Pharmacology & Experimental Therapeutics, and Medical Genetics, Mayo Clinic, Rochester, Minn (Dr Terzic).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

MicroRNA Expression Patterns to Differentiate Pancreatic Adenocarcinoma From Normal Pancreas and Chronic Pancreatitis
Mark Bloomston, Wendy L. Frankel, Fabio Petrocca, Stefano Volinia, Hansjuerg Alder, John P. Hagan, Chang-Gong Liu, Darshna Bhatt, Cristian Taccioli, and Carlo M. Croce
JAMA. 2007;297(17):1901-1908.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

MicroRNAs: tools for cancer diagnostics
Paranjape et al.
Gut 2009;58:1546-1554.
ABSTRACT | FULL TEXT  

Germline mutation of microRNA-125a is associated with breast cancer
Li et al.
J. Med. Genet. 2009;46:358-360.
ABSTRACT | FULL TEXT  

MicroRNA Signatures as Diagnostic and Therapeutic Targets
Waldman and Terzic
Clin. Chem. 2008;54:943-944.
FULL TEXT  

miRNAs: Effectors of Environmental Influences on Gene Expression and Disease
Hudder and Novak
Toxicol Sci 2008;103:228-240.
ABSTRACT | FULL TEXT  

MicroRNA Expression Profiles Associated With Prognosis and Therapeutic Outcome in Colon Adenocarcinoma
Schetter et al.
JAMA 2008;299:425-436.
ABSTRACT | FULL TEXT